Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Company Overview

Akebia Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach. The company has partnered with Otsuka Pharmaceutical for filing and commercialization of vadadustat in the United States, while Mitsubishi Tanabe Pharma holds rights to develop and commercialize the compound in ex-Japan territories. These alliances leverage Akebia’s scientific expertise alongside the global commercialization networks of its partners.

In addition to its focus on anemia in kidney disease, Akebia evaluates novel mechanisms of action aimed at improving kidney health and patient outcomes. The company maintains clinical trial sites across North America and engages with healthcare providers, academic institutions and patient advocacy groups to support the design and execution of its studies. Under the leadership of President and Chief Executive Officer John P. Butler, Akebia continues to build its development infrastructure and prepare for potential regulatory milestones.

Key Stats

• Today's Range: $2.99 to $3.07
• 50-Day Range: $2.68 to $3.19
• 52-Week Range: $1.52 to $4.08
• Volume: 1.35 million shs
• Average Volume: 2.58 million shs
• Market Capitalization: $803.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.75
• Consensus Rating: Moderate Buy

Akebia Therapeutics Stock Analysis - MarketRank™

Akebia Therapeutics scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Akebia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Akebia Therapeutics has a consensus price target of $6.75, representing about 122.8% upside from its current price of $3.03.

Amount of Analyst Coverage

Akebia Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akebia Therapeutics is -17.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akebia Therapeutics is -17.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.09% of the outstanding shares of Akebia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Akebia Therapeutics has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akebia Therapeutics does not currently pay a dividend.

Dividend Growth

Akebia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.35

Percentage of Shares Shorted

11.09% of the outstanding shares of Akebia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Akebia Therapeutics has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Akebia Therapeutics has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.69

News Sentiment

Akebia Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 26 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.

MarketBeat Follows

7 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Akebia Therapeutics is held by insiders.

Percentage Held by Institutions

Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

AKBA Stock Analysis - Frequently Asked Questions

How have AKBA shares performed this year?

Akebia Therapeutics' stock was trading at $1.90 at the start of the year. Since then, AKBA stock has increased by 59.5% and is now trading at $3.03.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.03) by $0.06. The biopharmaceutical company earned $57.34 million during the quarter, compared to the consensus estimate of $44.88 million.
Read the conference call transcript.

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.16%), SG Americas Securities LLC (0.04%), KLP Kapitalforvaltning AS (0.02%) and Voya Investment Management LLC (0.02%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman, Erik Ostrowski, Nicholas Grund and Richard C Malabre.
View institutional ownership trends.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 10/25/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKBA
• CIK: 1517022
• Web: www.akebia.com
• Phone: (617) 871-2098
• Fax: 617-871-2099
• Employees: 430
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Akebia Therapeutics: $6.75
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +122.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.41 million
• Net Margins: -17.91%
• Pretax Margin: -17.91%
• Return on Equity: N/A
• Return on Assets: -13.47%

Debt

• Debt-to-Equity Ratio: 1.61
• Current Ratio: 1.98
• Quick Ratio: 1.84

Sales & Book Value

• Annual Sales: $160.18 million
• Price / Sales: 5.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.23) per share
• Price / Book: -13.17

Miscellaneous

• Outstanding Shares: 265,140,000
• Free Float: 257,191,000
• Market Cap: $803.37 million
• Optionable: Optionable
• Beta: 0.68